Anti-Mouse IL-21R [Clone 4A9] — Purified in vivo GOLD™ Functional Grade
Anti-Mouse IL-21R [Clone 4A9] — Purified in vivo GOLD™ Functional Grade
Product No.: I-478
Clone 4A9 Target IL-21R Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Interleukin-21 Receptor Subunit, CD360 Isotype Rat IgG2a κ Applications FA , FC , in vivo , IP |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Rat YB2/0 hybridoma transfectant cell line expressing truncated IL-21R Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Additional Applications Reported In Literature ? IP, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 4A9 activity is directed against murine Interleukin-21 Receptor (CD360). Background Interleukin-21 receptor (IL-21R) is a single pass type I membrane protein and a member of the type I cytokine receptor family. It is the receptor for Interleukin-21 (IL-21) and upon binding forms a heterodimer with the common gamma subunit (CD132; IL-2RG). IL-21R and IL-21 are important for the proliferation and differentiation of B cells, T cells, and natural killer cells. They function in survival signalling for antiviral CD8+ T cells during chronic infections and induce growth and differentiation of mature B cells in Ig-secreting plasma cells. Additionally, they prevent T cell exhaustion and viral persistence by limiting virus driven Treg cell proliferation1. IL-21 and IL21-R function as early as the pro-B cell stage, with receptor-mediated signalling increasing as cells mature2. When IL-21R binds IL-21, the JAK/STAT transduction pathway is activated.
4A9 was generated by immunizing Lewis rats with IL-21R-transfected YB2/0 and subsequent fusion of immunized spleen cells to SP2/03. FACS analysis and immunoprecipitation studies show that 4A9 selectively binds to IL-21R. Additionally, 4A9 stains the majority of spleen cells from wild type C57BL/6 mice but not IL-21R deficient mice. IL-21 blocks the binding of 4A9 to IL-21R-transfected YB2/0 cells. Antigen Distribution IL-21R is expressed on most B cells as well as some T cells and NK cells. Ligand/Receptor IL-21 NCBI Gene Bank ID UniProt.org Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 4A9 is most commonly used in vivo in mice as a blocking antibody against mouse Interleukin-21 Receptor (IL-21R, also known as CD360) to inhibit IL-21-mediated signaling pathways. Key in vivo applications include:
Additional validated uses (in support of, but not exclusive to in vivo work):
Summary Table: Main In Vivo Applications of Clone 4A9 in Mice
Clone 4A9 is prepared with ultra-low endotoxin levels to ensure compatibility with sensitive in vivo mouse studies and minimize off-target responses. The antibody is typically a rat IgG2a isotype, and is administered using standard in vivo antibody techniques for preclinical research. Commonly, 4A9 refers to the mouse monoclonal antibody targeting Aldolase C, a glial cytosolic protein. In the literature, the most frequently used antibodies or proteins together with 4A9 are:
Other commonly used antibodies in studies involving Aldolase C and/or neural cell identification may include:
Key proteins and markers routinely paired with 4A9 in neural tissue studies:
Applications and detection methods:
In summary, Aldolase C antibody clone 4A9 is frequently used alongside MAP2 and Vimentin antibodies, as well as nuclear stains like DAPI, to distinguish neuronal and glial populations during neuroanatomical analyses in rodent tissue. Clone 4A9 is most prominently referenced in scientific literature as a monoclonal antibody targeting immune receptors in mouse models, specifically anti-mouse IL-21R and anti-mouse Mincle. Key findings from citations involving clone 4A9 in the literature include:
These antibodies have enabled precise characterization of immune cell subsets, receptor function, and ligand/receptor interactions, which are foundational for immunology research in mouse models. No evidence from search results indicates off-target reactivity or major controversies in the scientific use of clone 4A9. If you require findings related to a specific disease model, antigen, or application, please clarify for a more targeted synthesis. Current literature identifies the clone as central to immunophenotyping and functional studies of mouse IL-21R and Mincle. Dosing regimens for clone 4A9 (monoclonal antibody targeting either Mincle or IL-21R, depending on context) are not standardized across different mouse models; instead, they are highly dependent on the experimental application (e.g., in vitro assays, flow cytometry, in vivo blockade) rather than the mouse strain or disease context. Key findings on dosing regimens:
Variation across models:
Summary Table: Clone 4A9 Dosing Contexts
In summary: The dosing regimen for clone 4A9 is dictated by experimental objective, not mouse model background, and a range of concentrations is applied depending on the assay, with documented in vivo doses for IL-21R blockade ranging from 25 μg/day to 500 μg/day for three days, but no guidance for further model-specific adjustment. References & Citations1. Schmitz I, Schneider C, Fröhlich A, et al. PLoS Pathog. 9(5):e1003362. 2013.
2. Simard N, Konforte D, Tran AH, et al. J Immunol. 186(9):5244-5253. 2011. 3. Jin H, Carrio R, Yu A, et al. J Immunol. 173(1):657-665. 2004. 4. DeKoter RP, Geadah M, Khoosal S, et al. J Immunol. 185(12):7374-7384. 2010. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
I-478 | |
I-852 | |
I-833 | |
I-1251 | |
I-839 | |
I-479 | |
I-1252 | |
I-1253 | |
I-1254 | |
I-1256 | |
I-481 |
